| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.0077 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.9 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.9 |